Mechanisms of disease: Angiogenesis in urologic malignancies

Nature Clinical Practice Urology

Volumn 3, Issue 3, 2006, Pages 157-169

  Charlesworth, Philip J S ^a   Harris, Adrian L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Bladder cancer; Prostate cancer; Renal cancer

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE; CETUXIMAB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOSTATIN; GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; NEUROPILIN 1; NEUROPILIN 2; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; THYMIDINE PHOSPHORYLASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTIGEN DETECTION; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; KIDNEY CANCER; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; STATISTICAL ANALYSIS; TUMOR GROWTH; URINARY TRACT CANCER;

HUMANS; KIDNEY NEOPLASMS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 33644884726     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0434     Document Type: Review

References (101)

1. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
2. Folberg R and Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112: 508-525
3. Ruoslahti E (2004) Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 32: 397-402
4. Durr E et al. (2004) Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 22: 985-992
5. Talks KL et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421
6. Bergers G and Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410
7. Bicknell R and Harris AL (2004) Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 44: 219-238
8. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
9. Brown NS and Bicknell R (1998) Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 334 (Pt 1): 1-8
10. Brown NS et al. (2005) Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: The effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer 92: 1696-1701
11. Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285
12. Wykoff CC et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083
13. Pruthi RS et al. (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review. J Urol 169: 2352-2359
14. Folkman J (2004) Endogenous angiogenesis inhibitors. APMIS 112: 496-507
15. Dameron KM et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584
16. Zhang L et al. (2000) Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60: 3655-3661
17. Sherif ZA et al. (2001) Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 8: 771-782
18. Ravi R et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44
19. Kerbel R and Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
20. Hlatky L et al. (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893
21. Fox SB and Harris AL (2004) Histological quantitation of tumour angiogenesis. APMIS 112: 413-430
22. Dickinson AJ et al. (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74: 762-766
23. Bochner BH et al. (1995) Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87: 1603-1612
24. Goddard JC et al. (2003) Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 9: 2583-2586
25. Inoue K et al. (2000) The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6: 4866-4873
26. Bernardini S et al. (2001) Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 166: 1275-1279
27. Crew JP et al. (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161: 799-804
28. Bakkar AA et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112
29. Crew JP et al. (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281-5285
30. van Rhijn BW et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64: 1911-1914
31. Theodoropoulos VE et al. (2005) Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95: 425-431
32. Hoskin PJ et al. (2003) GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89: 1290-1297
33. Onita T et al. (2002) Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 8: 471-480
34. Arima J et al. (2000) Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 88: 1131-1138
35. Neal DE et al. (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625
36. Yoshimura R et al. (2001) Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 165: 1468-1472
37. Neal DE et al. (1985) Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1: 366-368
38. Maeda K et al. (2001) Angiogenin expression in superficial bladder cancer. Hinyokika Kiyo 47: 547-552
39. Karashima T et al. (2003) Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9: 2786-2797
40. Grossfeld GD et al. (1997) Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer lnst 89: 219-227
41. Durkan GC et al. (2001) Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 7: 3450-3456
42. Guan KP et al. (2003) Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61: 719-723
43. Durkan GC et al. (2003) Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res 9: 2576-2582
44. Yamanaka M et al. (2001) Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 166: 2495-2499
45. Yagasaki H et al. (2003) Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 10: 220-227
46. Pantuck AJ et al. (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 9: 4641-4652
47. Na X et al. (2003) Overproduction of vascular endothelial growth factor related to von Hippel - Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170: 588-592
48. Edgren M et al. (1999) Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 19: 869-873
49. Jacobsen J et al. (2004) Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93: 297-302
50. Lidgren A et al. (2005) The expression of hypoxia-inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11: 1129-1135
51. Turner KJ et al. (2002) Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel - Lindau gene mutation. Cancer Res 62: 2957-2961
52. Raval RR et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel - Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686
53. Kim HL et al. (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173: 1496-1501
54. Bui MH et al. (2004) Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171: 2461-2466
55. Atkins M et al. (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721
56. Bonfanti A et al. (2000) Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer. Int J Biol Markers 15: 161-164
57. Motzer RJ et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21: 99-101
58. Rasmuson T et al. (2001) Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 37: 2199-2203
59. Dosquet C et al. (1997) Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3: 2451-2458
60. Matsumoto K et al. (2003) Prognostic significance of plasma placental growth factor levels in renal cell cancer: An association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 23: 4953-4958
61. Suzuki K et al. (2001) Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res 29: 7-12
62. Lee JS et al. (2001) Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol 77: 55-60
63. Shvarts O et al. (2005) p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173: 725-758
64. Miyata Y et al. (2003) Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 9: 1734-1740
65. Hemmerlein B et al. (2004) Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas. Histopathology 45: 603-611
66. Miyata Y et al. (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9: 1741-1749
67. Cho NH et al. (2003) Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44: 560-566
68. Fukata S et al. (2005) Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103: 931-942
69. Borre M et al. (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78: 940-944
70. Bono AV et al. (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5: 123-127
71. Heidtmann HH et al. (1999) Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81: 1269-1273
72. Borre M et al. (2000) Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 6: 1882-1890
73. Kuniyasu H et al. (2000) Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6: 2295-2308
74. Duque JL et al. (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523-527
75. Du Z et al. (2003) Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 116: 1936-1939
76. Quinn DI et al. (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41: 858-887
77. Mazzucchelli R et al. (2000) Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79
78. Ismail AH et al. (2004) Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. Can J Urol 11: 2146-2150
79. Meyer GE et al. (1995) Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76: 2304-2311
80. Walsh K et al. (1999) Angiogenic peptides in prostatic disease. BJU Int 84: 1081-1083
81. Trojan L et al. (2004) Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 32: 97-103
82. West AF et al. (2001) Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinicopathologic parameters in human prostate cancer. Br J Cancer 85: 576-583
83. Sunderkotter C et al. (1994) Macrophages and angiogenesis. J Leukoc Biol 55: 410-422
84. Lissbrant IF et al. (2000) Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival. Int J Oncol 17: 445-451
85. Sivridis E et al. (2002) Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: Correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 86: 1465-1471
86. Fidler IJ (2001) Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 93: 1040-1041
87. Murphy C et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127
88. Lehrer S et al. (2004) Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 3: 411
89. Abdulkadir SA et al. (2000) Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 31: 443-447
90. Wikstrom P et al. (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-275
91. Nicholson B and Theodorescu D (2004) Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91: 125-150
92. Strohmeyer D et al. (2000) Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45: 216-224
93. Mehta R et al. (2001) Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7: 81-88
94. The Strategy Group of the Program for the Assessment of Clinical Cancer Tests and the National Cancer Institute EORTC Clinical Tumor Marker Study Publications Guidelines. [http://www.cancerdiagnosis. nci.nih.gov/ assessment/progress/clinical.html] (online 15 February 2002)
95. Sanchez-Carbayo M (2004) Recent advances in bladder cancer diagnostics. Clin Biochem 37: 562-571
96. Takahashi M et al. (2003) Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res 89: 157-181
97. Gelmann EP and Semmes OJ (2004) Expression of genes and proteins specific for prostate cancer. J Urol 172 (Suppl): S23-S27
98. Yang CC et al. (2003) Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement. J Clin Lab Anal 17: 85-89
99. Cox MC et al. (2005) Angiogenesis and prostate cancer: Important laboratory and clinical findings. Curr Oncol Rep 7: 215-219
100. Retter AS et al. (2003) The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer 2: 153-159
101. Macpherson GR et al. (2002) Antiangiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Rev 21: 93-106